Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$1.42
-$0.02(-1.30%)
At close: 4:00 PM EST
$1.42
-$0.02(-1.30%)
Day’s Range― - ―
52-Week Range$0.80 - $4.85
Previous CloseN/A
Volume92.55K
Average Volume (3M)1.72M
Market Cap
$112.73M
Enterprise Value$170.87
Total Cash (Recent Filing)$13.21M
Total Debt (Recent Filing)$85.39M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 04, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding69,587,840
10 Day Avg. Volume2,628,731
30 Day Avg. Volume1,718,206
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside252.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$161.08M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & System PlacementsA pronounced rebound in top-line and higher system shipments indicate expanding clinical adoption and an enlarging installed base. That durable growth supports recurring consumables, service revenue, and referral effects, improving unit economics and long‑term revenue visibility if adoption persists.
Sustainably High Gross MarginsConsistently strong gross margins imply favorable product-level economics and pricing power for NeuroStar systems and consumables. High contribution margins provide structural room to invest in sales/clinical support while moving toward breakeven as fixed opex is controlled and utilization rises.
Payer/regulatory Expansion Widens Addressable MarketPolicy change enabling nurse practitioners to order and deliver TMS materially increases access in primary and underserved settings. This structural reimbursement expansion lowers provider bottlenecks, enlarges the target patient pool, and supports sustained adoption and recurring treatment volumes over months to years.
Bears Say
Material Cash Burn And Low LiquidityA modest cash balance combined with a full-year guidance of negative operating cash flow creates a persistent funding need. Over 2–6 months this raises refinancing or dilution risk, constrains investment in commercialization, and makes execution on growth and cost initiatives contingent on raising capital or rapid cash-flow improvement.
Persistent UnprofitabilityDespite improving trends, materially negative margins indicate the business is not yet self-sustaining. Continued operating losses limit retained earnings, hinder equity rebuilding, and force reliance on external financing until revenue scale, utilization, and cost discipline combine to produce sustained positive EBITDA and net income.
Elevated Leverage And Thin Equity CushionEven after reducing nominal debt, the company retains elevated leverage due to a small equity base. This limits financial flexibility, raises solvency risk under further stress, and makes future balance-sheet support (debt or equity raises) more dilutive or costly until profitability and equity rebuild occur.
Neuronetics News
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.80 and its highest was $4.85 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $112.73M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Aug 04, 2026 which is in 15 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on May 05, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.174 by $0.014.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.12.
How many shares outstanding does Neuronetics have?
Neuronetics has 69,587,840 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.174. Following the earnings report the stock price went up 7.426%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (252.11% Upside)
$5.00 (252.11% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 56.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.2%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.65%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
STIM Stock 12 Month Forecast
Average Price Target
$5.00
▲(252.11% Upside)
Technical Analysis
Ownership Overview
30.44% Insiders
5.57% Mutual Funds
0.08% Other Institutional Investors
60.45% Public Companies and
Individual Investors